Karen Costenbader, MD, discusses how early intervention with belimumab in patients with lupus significantly reduces disease flares and prevents irreversible organ damage.
Oral brepocitinib fails to meet primary endpoint in phase 2 lupus study healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.
Roivant (ROIV) and Priovant announced the Phase 2 study evaluating oral brepocitinib in adult patients with moderate to severe active lupus did not meet its primary endpoint of Systemic Lupus Erythematosus Responder Index change of 4 at Week 52.
Oral brepocitinib failed to meet its primary endpoint of Systemic Lupus Erythematosus Responder Index change of 4 at Week 52Priovant plans to continue progressing the program in indications outside.
Roivant ends long shot lupus program after phase 2 fail fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.